Creative Biolabs provides anti blood-brain barrier

The BBB is a selective interface that restricts movement of molecules between the bloodstream and central nervous system. This barrier imposes a major challenge to the development of therapies for neurological diseases, large molecules in particular, due to the limited ability with which they can penetrate through the BBB. Single domain antibodies are considered as very promising antigen-binding moieties for molecular imaging and therapeutic purposes because of their favorable pharmacological and pharmacokinetic properties. Single domain antibodies have been demonstrated to be able to cross the BBB without treatment, so they can be used as vectors to target drugs or therapeutic peptides into the brain.